Pharvaris Reports 83% Attack Reduction In CHAPTER-3, As FDA Verdict On Deucrictibant’s Other Formulation Awaits

Pharvaris has added a second late-stage win for deucrictibant, reporting positive phase 3 results for a once-daily extended-release formulation in hereditary angioedema. The update gives the Swiss biotech fresh efficacy support for its broader attempt to build an oral treatment franchise across both acute attacks and long-term prophylaxis.

The timing matters because Pharvaris is already in front of the FDA with an immediate-release formulation of deucrictibant for treatment of HAE attacks. That application, filed in July, carries an April 23, 2027 decision date.

The data

CHAPTER-3 evaluated a 40-mg once-daily extended-release formulation of Pharvaris’ oral bradykinin B2 receptor antagonist against placebo in 85 patients with HAE type 1, HAE type 2 or HAE with normal C1 inhibitor. Pharvaris said the study met its primary endpoint, showing an 83% reduction in the rate of monthly attacks compared with placebo after 24 weeks.

In the subgroup of 80 patients with HAE type 1 or 2, the reduction was 87%, according to the company. Pharvaris also said deucrictibant met all secondary endpoints, including the number of attacks treated with on-demand medication, the number of severe attacks and the proportion of time without angioedema symptoms.

The strategic picture

Pharvaris had already reported a separate phase 3 win for immediate-release deucrictibant in December 2025, supporting the drug’s use as an on-demand treatment for swelling episodes and related symptoms in HAE. With CHAPTER-3 now positive, the company has evidence behind both formulations it wants to use in the disease.

That is the core strategic signal from this readout. Rather than advancing a single oral product into a market still shaped by injectables, Pharvaris is trying to offer one branded franchise that could cover both attack treatment and prevention. If that holds up through regulatory review, it could give HAE patients an oral alternative not only for acute management but also for prophylaxis.

For the near term, the regulatory sequence still runs through the immediate-release filing. Pharvaris said it plans to submit an NDA for deucrictibant as a prophylactic for bradykinin-mediated angioedema attacks in the first half of 2027. If the immediate-release product is approved, it would compete with KalVista’s Ekterly, which the source describes as an existing oral HAE attack treatment.

Pharvaris’ stock was up 14% to $41.44 after markets opened, versus a $35.25 close on Friday, indicating investors read the result as more than a single-study win. The company now has a clearer argument that oral therapy in HAE may not be limited to one treatment setting.